INAB
NASDAQ:INABNASDAQ
1 announcements
Credibility Score65%
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
OverhypedModerate hypeunclear
Repeat-dose gamma-delta T cell therapy shows doubled survival in glioblastoma versus standard care.
13 minutes ago
▼